2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2642

Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2613

Patient Reported Physical Capacity Correlates with Phenylalanine Serum Levels in Patients with Early Untreated Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2476

Patient-Reported Cognitive Impairment, Pain, and Depressive Symptoms in Patients with Systemic Lupus Erythematosus and Comorbid Depression

Psychology/Social Sciences (ARHP)

9:00AM-11:00AM: Abstract Number: 2730

Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 3053

Patients Treated for Behcet Syndrome in the US Have Higher Disease Activity Scores at Presentation If They Fulfill ISG Criteria and If They Are Females, However Have Less Severe Disease Overall

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2333

Patients’ Prioritization of Patient-Centered Education and Research Topics in Rheumatic Disease

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2956

Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2525

Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2959

Patterns of Vascular Brain Injury in Systemic Lupus Erythematosus Patients with Ischemic Stroke: Impact on Neuropsychological, Neurobehavioral and Physical Function Outcome

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 3073

Patterns of Vascular Involvement in Childhood Takayasu Arteritis

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2418

Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2443

Pediatric Tele-Rheumatology: A Pilot Project to Assess Accuracy of Physical Examination Findings and Diagnostic Concordance at a Distance

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2177

Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro

Antiphospholipid Syndrome: Basic Science

9:00AM-11:00AM: Abstract Number: 2321

Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2245

Periarticular Bone Mineral Density Predicts Structural Progression of Knee Osteoarthritis Independently of Static Alignment

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].